Clinics and Practice, Journal Year: 2025, Volume and Issue: 15(3), P. 65 - 65
Published: March 17, 2025
Alpha-synuclein has been associated with neurodegeneration, especially in Parkinson’s disease (PD). This study aimed to review clinical, biochemical, and neuroimaging markers management of prodromal synucleinopathies. The state synucleinopathies can be better understood PD pathophysiology, it separated into premotor pre-diagnostic phases. incidence patients phase symptoms ranges from 0.07 14.30, the most frequently studied pathology is REM behavioral disorder (RBD). Neuroimaging are related dopamine denervation, brain perfusion changes, gross anatomy peripheral abnormalities. α-synuclein assays (SAA) CSF revealed high sensitivity (up 97%) specificity 92%); last decade, there was development other matrices (blood, skin, olfactory mucosa) for obtaining quantitative qualitative α-synuclein. Other biomarkers neurofilament light chain, DOPA decarboxylase, multiplexed mass spectrometry assay. Regarding genetic counseling α-synucleinopathies, an important topic clinical practice discuss high-risk individuals should involve basic principles autonomy, beneficence, non-maleficence. Some themes that reviewed involvement physical activity, diet (including alcohol, coffee, vitamin supplementation), smoking, sleep, stress pathophysiology number trials still scarce, studies evaluating intervention even lower.
Language: Английский